

SUPPLEMENTARY REFERENCES – RECOMMENDED READING

S1 Mizokami-Stout, K., Cree-Green, M., Nadeau, K.J. Insulin resistance in type-2 diabetic youth. *Curr Opin Endocrinol Diabetes Obes* 2012, **19**: 255-62

S2 Cavaghan, M.K., Ehrmann, D.A., Polonsky, K.S. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. *J Clin Invest* 2000, **6**: 329-333

S3 Meigs, J.B., Muller, D.C., Nathan, D.M., Blake, D.R., Andres, R. The natural history of progression from normal glucose tolerance to type-2 diabetes in the Baltimore longitudinal study of aging. *Diabetes* 2003, **52**: 1475-1484

S4 Verspohl, E.J. Novel pharmacological approaches to the treatment of type 2 diabetes. *Pharmacol Rev* 2012, **64**: 188-237

S5 Nathan, D.M. Long-term complications of diabetes mellitus. *N Engl J Med* 1993, **328**: 1676-1685

S6 Ramlo-Halsted, B.A., Edelman, S.V. The natural history of type-2 diabetes mellitus: implications for clinical practice. *Clinics of North America Primary Care* 1999, **26**: 771-789

S7 Hwang, Y.C., Jee, J.H., Kang, M., Rhee, E.J., Sung, J., Lee, M.K. Metabolic syndrome and insulin resistance are associated with abnormal left ventricular diastolic function and structure independent of blood pressure and fasting plasma glucose level. *Int J Cardiol* 2012, **159**: 107-11

S8 Gami, A.S., Witt, B.J., Howard, D.E., Erwin, P.J., Gami, L.A., Somers, V.K., Montori, V.M. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol* 2007, **49**: 403-14

S9 Kahn R. Metabolic syndrome: Is it a syndrome? Does it matter? *Circulation* 2007, **115**: 1806-1810

S10 Kalra, S.P. Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation *Peptides* 2009, **30**: 1957-1963

S11 Keymel, S., Heinen, Y., Balzer, J., Rassaf, T., Kelm, M., Lauer, T., Heiss, C. Characterization of macro- and microvascular function and structure in patients with type-2 diabetes mellitus. *Am J Cardiovasc Dis* 2011, **1**: 68-75

S12 The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med* 2011, **364**: 818-28

S13 The ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008, **358**: 2560-2572

S14 Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., Zieve, F.J., Marks, J., Davis, S.N., Hayward, R., Warren, S.R., Goldman, S., McCarren, M., Vitek, M.E.,

Henderson, W.G., Huang, G.D. Glucose control and vascular complications in veterans with type-2 diabetes. *N Engl J Med* 2009, **360**: 129-39

S15 Chokrungvaranon, N., Deer, J., Reaven, P.D. Intensive glycemc control and cardiovascular disease: are there patients who may benefit? *Postgrad Med* 2011, **123**: 114-23

S16 Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A.W. 10-year follow-up of intensive glucose control in type-2 diabetes. *N Engl J Med* 2008, **359**: 1577-89

S17 Culler, M.D. Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors. *Horm Metab Res* 2011, **43**: 854-7. Epub 2011 Oct 11

S18 Tremblay, M., Gaudet, D., Brisson, D. Metabolic Syndrome and Oral Markers of Cardiometabolic Risk *J Can Dent Assoc* 2011, **77**: 1-7

S19 Zamora, A., Marrugat, J. Prognosis of diabetic patients with coronary heart disease. *Rev Esp Cardiol* 2002, **55**: 751-62

S20 Capewell, S., Buchan, I. Why have sustained increases in obesity and type 2 diabetes not offset declines in cardiovascular mortality over recent decades in Western countries? *Nutr Metab Cardiovasc Dis* 2012, **22**: 307-311

S21 Ortega, F.B., Lee, D., Katzmarzyk, P.T., Ruiz, J.R., Sui, X., Church, T.S., Blair, S.N. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. *Eur Heart J* 2012, **10.1093**: 1-10

S22 Stang, A. Causality and confounding in epidemiology. *Gesundheitswesen* 2011, **73**: 884-7

S23 Kovesdy, C.P., Kalantar-Zadeh, K. Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. *Adv Chronic Kidney Dis* 2012, **19**: 11-8

S24 Lucas, R.M., McMichael, A.J. Association or causation: evaluating links between "environment and disease". *Bull World Health Organ* 2005, **83**: 792-5

S25 Warnock, D.G., Muntner, P., McCullough, P.A., Zhang, X., McClure, L.A., Zakai, N., Cushman, M., Newsome, B.B., Kewalramani, R., Steffes, M.W., Howard, G., McClellan, W.M. Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. *Am J Kidney Dis* 2010, **56**: 861-871

S26 Krishna, R., Schaefer, H.G., Bjerrum, O.J. Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development. *Eur J Pharm Sci* 2007, **31**: 62-67

S27 Atkinson Jr, A.J., Lyster, P.M. Systems clinical pharmacology. *Clin Pharmacol Ther* 2010, **88**: 3-6

S28 Cefalu, W.T. Glycemic Targets and Cardiovascular Disease. *N Engl J Med* 2008, **358**: 2633-2635

S29 Della Pasqua, O. PKPD and disease modelling: Concepts and applications to oncology. In H.H.C. Kimko and C.C. Peck (eds.) *Clinical Trial Simulations*, AAPS Advances in the Pharmaceutical Sciences Series 1, DOI 10.1007/978-1-4419-7415-0_13, Springer Science & Business Media, LLC, p. 277-306, 2011

S30 Hanahan, D., Weinberg, R.A. Hallmarks of cancer: the next generation. *Cell* 2011, **144**: 646-674

S31 ORIGIN Trial Investigators, Gerstein, H.C., Bosch, J., Dagenais, G.R., Díaz, R., Jung, H., Maggioni, A.P., Pogue, J., Probstfield, J., Ramachandran, A., Riddle, M.C., Rydén, L.E., Yusuf, S. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med* 2012, **367**: 319-328